Paul A. Friedman, M.D.

The purpose of the study is to determine whether voice recordings acquired from patient-owned Android and Apple (iOS) smartphones can be used to monitor cardiovascular health. Voice signals will be processed to determine whether we can detect presence of cardiovascular disease and wellness, or if health risks exist. Electrocardiograms (ECGs) will be collected from those who choose to share and have an Apple Watch version 4 or greater with ECG capability, not SE. iOS users will have the option to submit activity data, clinical data, and sensor usage (ex: movement, ambient light sensors, optical and electrical data collected for heart rate detection and ECG). Your health, and wellness will be followed for up to 5- years or longer if you choose to remain in the study.

The Mayo Clinic CV Research study app will transmit your voice/speech data, Health app data, and Apple Watch ECGs collected as part of this research in a secure manner from your iOS smartphone and Apple Watch to Mayo Clinic. Android users at this time will only be able to transmit voice/speech data. Your data will be stored in a secure research database. Your speech sample will not be part of your medical record. If you decide to send ECGs recorded with your Apple watch version 4 or greater, your provider can review your ECGs in the Cardiology tab under AI-ECG Dashboard in your Mayo Clinic medical record, although you will need to notify your care provider of participation.

To access the CV Research app you can go directly to your Apple app store or Play Store for Android and search for: Mayo Clinic CV Research app. After you download the Mayo Clinic CV Research app, sign into the app using your patient services username and password. Please contact the study team if you have any questions: Voicestudy@mayo.edu. Thank you for participating in the Heart and Voice study.

Paul Friedman, MD, Brad Leibovich, MD, Zachi Attia Ph.D., and Jennifer Dugan

The purpose of this study is to evaluate the safety and effectiveness of the AveirTM Dual-Chamber (DR) Leadless Pacemaker (LP) system in patients indicated for a DDD(R) pacemaker to support regulatory approval for the Aveir DR LP system for DDD(R) pacing indications and the Aveir atrial LP for AAI(R) pacing indications.

The purpose of this study is to determine whether a wristband that detects your pulse can detect your heart rate and rhythm similar to electrocardiograms (ECG).

The purpose of this study is to modify and adapt the algorithm to be usable in a mobile form factor with a limited number of leads. For this, will prospectively test and validate the adapted algorithm in outpatients presenting to the echocardiography laboratory and to test the sensitivity and specificity of a single lead ECG to identify people with decreased left ventricular EF.

The purpose of this study is to determine the accuracy of a non-invasive approach to estimate potassium levels using surface ECG's from patients undergoing hemodialysis.

The purpose of this study is to gather information to understand the effect of body position on ECGs using artificial intelligence.

The purpose of this study is to assess cardiovascular health and detect unknown and asymptomatic diseases using Mayo AI-ECG algorithms.

We hypothesize that using single lead ECGs and symptoms data collected by patients using their personal Apple Watch (FDA approved for AF detection) via a Mayo Clinic app, will allow data to be shared within a dashboard in Epic, so physicians may have a way to remotely assess cardiovascular health.

The primary purpose of this study is to explore KardiaK performance in a controlled and comprehensive clinical setting, including collection of relevant data such as patient medical history, and medications affecting potassium.  In addition, it is intended to explore KardiaK performance when serial ECGs are recorded and to explore KardiaK performance using a 12-lead ECG and two novel ECG recording devices designed for home use.

The purpose of this study is to assess the serum potassium and cardiac rhythm trends in subjects with end stage renal disease (ESRD) who are on 3 times weekly maintenance hemodialysis for at least 60 days.

The purpose of this study is to observe the remote ECG signals of Nanostim pacemaker patients utilizing the AliveCor device, and compare these ECG signals with ECG recordings collected with the Nanostim device programmer during their clinical follow-up.

An important means to control the COVID-19 pandemic is the rapid identification of infected individuals to allow quarantine and therapy to be promptly delivered.  At home testing will soon be available, but requires reagents and introduces a delay.  The possibility of combining a limited number of Mid-Turbinate (MT) nasal swab tests, Dried Blood Spot (DBS) serology, and smartphone-enabled electrocardiogram (ECG) tests may permit daily rapid, under one minute tests potentially, if this method proves to be effective. We plan to enroll 900 participants to determine if we can detect conversion in all modalities.

This is a prospective, non-randomized, multicenter, pivotal Investigational Device Exemption (IDE) study. The intent of this study is to demonstrate the safety and effectiveness of the ST Monitoring Feature in St Jude Medical ICD systems.

Prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.